RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation

Author:

Sivakumar Pitchumani,Thompson John Ryan,Ammar Ron,Porteous Mary,McCoubrey Carly,Cantu Edward,Ravi Kandasamy,Zhang Yan,Luo Yi,Streltsov Denis,Beers Michael F.,Jarai Gabor,Christie Jason D.

Abstract

Idiopathic pulmonary fibrosis (IPF), the scarring of lung parenchyma resulting in the loss of lung function, remains a fatal disease with a significant unmet medical need. Patients with severe IPF often develop acute exacerbations resulting in the rapid deterioration of lung function, requiring transplantation. Understanding the pathophysiological mechanisms contributing to IPF is key to develop novel therapeutic approaches for end-stage disease.We report here RNA-sequencing analyses of lung tissues from a cohort of patients with transplant-stage IPF (n=36), compared with acute lung injury (ALI) (n=11) and nondisease controls (n=19), that reveal a robust gene expression signature unique to end-stage IPF. In addition to extracellular matrix remodelling pathways, we identified pathways associated with T-cell infiltration/activation, tumour development, and cholesterol homeostasis, as well as novel alternatively spliced transcripts that are differentially regulated in the advanced IPF lung versus ALI or nondisease controls. Additionally, we show a subset of genes that are correlated with percent predicted forced vital capacity and could reflect disease severity.Our results establish a robust transcriptomic fingerprint of an advanced IPF lung that is distinct from previously reported microarray signatures of moderate, stable or progressive IPF and identifies hitherto unknown candidate targets and pathways for therapeutic intervention in late-stage IPF as well as biomarkers to characterise disease progression and enable patient stratification.

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference41 articles.

1. Idiopathic pulmonary fibrosis;Martinez;Nat Rev Dis Primers,2017

2. Pirfenidone for the treatment of idiopathic pulmonary fibrosis;George;Expert Rev Clin Pharmacol,2017

3. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis;Rogliani;Pulm Pharmacol Ther,2016

4. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis;Tomioka;Respirol Case Rep,2017

5. Severe idiopathic pulmonary fibrosis: what can be done?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3